Totally disagree with you! senolytics likely have the the MOST value in the context of cancer therapy, imo. At least as long as humans are still getting cancers, and those cancers are treated with chemo and/or radiation -- therapies which are known to cause cellular senescence in healthy tissue. In these cases, it's also demonstrated that senescent cells in the tumor periphery/microenvironment directly facilitate relapse and metastasis. Senolytics should be given as adjuvant to any cancer therapy.

In aging humans, the senescent cell burden is problematic because of sterile low-grade inflammation. In the context of cancer, it's directly promoting cancer growth and recurrence. Different value.